The Online Investor

Slideshow Mergers & Acquisitions

By The Online Investor Staff, updated Sun., Jan. 29, 6:21 PM

Slide #58. Calyxt, Inc. Cibus

Acquirer: Calyxt, Inc. (NASDAQ:CLXT)
Acquiree: Cibus
Details: Calyxt, Inc. (Nasdaq: CLXT), a plant-based synthetic biology company, and Cibus, a leader in precision gene editing in agriculture, today announced that both companies have entered into a definitive merger agreement under which Calyxt and Cibus will merge in an all-stock transaction. The merger will create a new industry-leading company that combines the two pioneers in agriculture-based gene editing and establishes one of the world's most sophisticated facilities for trait development and next-generation plant breeding.

Calyxt is a plant-based synthetic biology company that utilizes its proprietary PlantSpring™ technology platform to engineer plant metabolism to produce plant-based chemistries for use in customers' materials and products. Co. is focused on developing these synthetic biology solutions for customers in differentiated end markets, including the cosmeceutical, nutraceutical, and pharmaceutical industries. Co. also out-licenses elements of the PlantSpring technology platform and may selectively develop products for customers in agriculture. Co.'s product, an improved digestibility alfalfa, was developed with and licensed to S&W Seed Company.

Open the CLXT Page at The Online Investor »

Company Name: 
Calyxt Inc
Number of ETFs Holding CLXT: 
Total Market Value Held by ETFs: 
Total Market Capitalization: 
% of Market Cap. Held by ETFs: 

Open the CLXT Page at The Online Investor (in a new window) »

Quotes delayed 20 minutes

Email EnvelopeFree CLXT Email Alerts:
Get SEC Filing Alerts
Get Dividend Alerts

Hold (2.00 out of 4)
0th percentile
(ranked lower than approx. 100% of all stocks covered)

Analysts' Target Price:
CLXT Stock Forecast

Based on Zacks ABR data;
powered by Xignite

Mergers & Acquisitions Page |

Copyright © 1998 - 2023, All Rights Reserved
Nothing in The Online Investor is intended to be investment advice, nor does it represent the opinion of, counsel from, or recommendations by BNK Invest Inc. or any of its affiliates, subsidiaries or partners. None of the information contained herein constitutes a recommendation that any particular security, portfolio, transaction, or investment strategy is suitable for any specific person. All viewers agree that under no circumstances will BNK Invest, Inc,. its subsidiaries, partners, officers, employees, affiliates, or agents be held liable for any loss or damage caused by your reliance on information obtained. By visiting, using or viewing this site, you agree to the following Full Disclaimer & Terms of Use and Privacy Policy. Video widget and stock market videos powered by Market News Video. Quote data delayed at least 20 minutes; data powered by Ticker Technologies, and Mergent. Contact The Online Investor; Meet Our Editorial Staff.